

SAGE UPDATE

BMGF'S work in support of the
Global Vaccine Action Plan (GVAP)

Dr. Orin Levine
18 October 2016

■ AGENDA

① BMGF's work in support of the Global Vaccine Action Plan

Progress toward our impact goals and ensuring accountability

Shaping thinking to accelerate progress

OUR ACTIVITIES IN SUPPORT OF GVAP



Vaccine Delivery

- Supply and pricing
- Country immunization
- Data for decision-making




Discovery & Vaccine Development

- Develop and deploy new/improved vaccines
- Regulatory approval



Disease-specific

- Support introduction & delivery
- Broaden vaccine access



Advocacy & Policy

- Advocate to governments and donor agencies
- Build demand and political will

VACCINE DELIVERY



VACCINE DEVELOPMENT



2015 DRI & Helixide Gates Foundation 7

POLICY & ADVOCACY



2015 DRI & Helixide Gates Foundation 8

DISEASE-SPECIFIC PROGRAMS



OUR ACTIVITIES IN SUPPORT OF GVAP

Vaccine Delivery

- Work with Gavi to introduce new vaccines
- Ensure sustainable supply and price
- Invest in partners who support country immunization
- Support use of high-quality immunization data for decision-making
- Strengthen supply chains
- Direct investments in India, Nigeria, Pakistan, Ethiopia



OUR ACTIVITIES IN SUPPORT OF GVAP

Vaccine Development

- Invest in the development, approval and deployment of new/improved vaccines
- Support innovations that simplify vaccine administration and use

Policy and Advocacy

- Build demand and political commitment for immunization across local, national and global levels
- Support evidence-based communications of vaccine safety and effectiveness



OUR ACTIVITIES IN SUPPORT OF GVAP

Disease-specific

- **Pneumococcal:** Broaden access; invest in newer, improved vaccines
- **Rotavirus:** Support introduction and delivery; ensure adequate supply
- **Polio:** Invest in development of multiple vaccines in push toward eradication
- **Pentavalent:** Reduce procurement cost; ensure sustainable supply
- **HPV:** Optimize Gavi-supported vaccine introduction; maximize coverage
- **Measles-Rubella:** Invest in two additional manufacturers to develop vaccines
- **Malaria:** Support potential introduction of vaccine and innovations for eradication

OUR ACTIVITIES IN SUPPORT OF GVAP

Disease-specific (continued)

- **Maternal Immunization:** Build evidence base and develop vaccines
- **Meningitis:** Support countries to deliver MenAfriVac™
- **Cholera:** Support the WHO's establishment of a global oral vaccine stockpile
- **HIV:** Support the global HIV vaccine pipeline at multiple levels
- **TB:** Invest in development and approval of more effective TB vaccines
- **Ebola:** Support outbreak control and emergency preparedness; accelerate R&D

FINANCIAL SUPPORT FOR GVAP

- BMGF commitment of **\$10 Billion** to Decade of Vaccines to:
 - **Rapidly scale** immunization programs
 - Conduct Research & Development
 - Ensure **steady market** for vaccines in developing countries
- Over \$8 Billion paid and committed as of October, 2015



■ AGENDA

BMGF's work in support of the Global Vaccine Action Plan (GVAP)

② Progress toward our impact goals and ensuring accountability

Shaping thinking to accelerate progress

GVAP GOALS

- Achieve a world free of polio
- Meet global and regional elimination targets
- Meet vaccination coverage targets everywhere
- Develop and introduce new & improved vaccines and technologies
- Exceed MDG 4-target for reducing child mortality

BMGF GOALS

- Eradicate polio
- Achieve 90% coverage nationally and 80% coverage in each district
- Improve existing vaccines and develop new ones
- Prevent >11M deaths



VACCINE DELIVERY 2017-2020 STRATEGY OVERVIEW

We will achieve our long term strategic goal ...

Prevent 11.3 million deaths,
3.8 million disabilities, and
230 million illnesses...

...through high, equitable,
sustainable vaccine
coverage (90/80)...

...and
support polio eradication (0)

... through strong, locally-owned immunization systems ...

... in countries with the greatest need ...


... supported by an ecosystem of partners ...

... to improve and sustain critical delivery system components ...


... supported by an innovative and engaged Vaccine Delivery team.

PROGRESS TOWARD 2020 IMPACT GOAL

2011 – 2015 Estimated Actual Impact




Drivers of difference between Estimated Actual and Projection



■ AMBITIOUS TARGETS TO REACH 2020 GOAL

- 55% of our 2020 goals depend on reaching every target over the next 4 years
- Key assumptions include:
 - Campaign effectiveness, especially MR, YF
 - Assumes 90% coverage in India, Nigeria, and DRC
 - High RI coverage

COUNTRIES DRIVING LARGEST 2017-2020 IMPACT



■ AGENDA

BMGF's work in support of the Global Vaccine Action Plan (GVAP)


Progress toward our impact goals and ensuring accountability

③ Shaping thinking to accelerate progress


■ KEYS TO ACCELERATING PROGRESS

- **Adjusting** course by assessing actual performance vs forecasts
- **Better governance using timely, local data** for decision making
- Inequities must be **accurately assessed** and addressed
- Immunization advocates **need to reframe approach** to expand upon progress to-date

BMGF EXAMPLES: COURSE CORRECTION BASED ON DATA



ASSOCIATION BETWEEN COVERAGE AND EQUITY



SUMMARY

- BMGF goals are aligned to GVAP goals
- BMGF monitoring progress and taking actions based on actuals vs. expected
- Reducing inequities starts with achieving high coverage
- Sub-national data are key to improving coverage & equity
- Lessons from polio can help focus coverage efforts

THANK YOU

